Application of doramectin in treatment of gliomas

A technology of doramectin and glioma, applied in the application field of doramectin in the treatment of glioma, can solve the problems that the effect of doramectin has not been reported, achieve good treatment and prognosis, and inhibit proliferation and migration, promote the effect of autophagy

Pending Publication Date: 2020-10-20
NORTHEAST AGRICULTURAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, the effect of doramectin in the treatment of glioma has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of doramectin in treatment of gliomas
  • Application of doramectin in treatment of gliomas
  • Application of doramectin in treatment of gliomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Verification that doramectin inhibits the growth of glioma cells U87 and C6 cells in vitro.

[0025] 1. Experimental method:

[0026] U87 and C6 cells in the logarithmic growth phase were treated with 3.0×10 3 The number of cells was seeded in a 96-well plate and placed in 37°C, 5% CO 2 Cultivate in the incubator for 24h;

[0027] Discard the old medium in the 96-well plate, wash the cells twice with PBS, and treat the cells with doramectin or chloroquine;

[0028] Place the 96-well plate in 37°C, 5% CO 2 Cultivate in a constant temperature incubator, take out the 96 plates that have been cultured for different times, suck out the liquid in the wells, and wash them twice with PBS;

[0029] Take out the 96-well plate, discard the MTT solution, and add 150 μL of DMSO solution to each well;

[0030] Put the 96-well plate in a shaker in the dark, and shake it for 30 minutes;

[0031] Detect the absorbance value of the microplate reader at a wavelength of 49...

Embodiment 2

[0036] Example 2: Verification that doramectin inhibits the migration of U87 and C6 cells.

[0037] 1. Experimental method:

[0038] U87 and C6 cells in the logarithmic growth phase were treated with 2.0×10 5 The number of cells was seeded in a 6-well plate and placed at 37°C, 5% CO 2 Cultivated in an incubator;

[0039] After the cell density reaches 80%, discard the culture medium, wash twice with PBS, draw a scratch of about 1 cm from top to bottom in the center of each well with a pipette tip, wash twice with PBS again, and put into an inverted microscope to take pictures;

[0040] After discarding the PBS, treat U87 and C6 cells with different concentrations of doramectin, and culture them in the incubator for 24 hours;

[0041] After the supernatant was discarded, washed twice with PBS, put into an inverted microscope to take pictures again, the experiment was repeated three times.

[0042] 2. Experimental results:

[0043] The results showed that the scratch dista...

Embodiment 3

[0046] Example 3: Verification of doramectin-induced apoptosis in U87 and C6 cells.

[0047] 1. Experimental method:

[0048] U87 and C6 cells in the logarithmic growth phase were treated with 1.0×10 5 The number of cells was seeded in a 6-well plate and placed in 37°C, 5% CO 2 Cultivate in the incubator for 24h;

[0049] After the cells were treated with different concentrations of doramectin or chloroquine for 48 hours, they were washed twice with pre-cooled PBS;

[0050] Add 0.5 mL of DAPI dye to the 6-well plate, and incubate at 37°C for 15 minutes in the dark;

[0051] The 6-well plate was washed 3 times with PBS for 10 min each time, detected and photographed with a fluorescence microscope, and the experiment was repeated three times.

[0052] 2. Experimental results:

[0053] The results showed that after the cells were treated with doramectin, obvious changes such as nuclear condensation and DNA fragmentation appeared in the cells. The apoptosis rate of U87 cells...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of new application of medicines, in particular to new application of doramectin in treatment of gliomas. Through in-vivo and in-vitro experiments, the anti-glioma effect of the doramectin is investigated. The doramectin can inhibit proliferation and migration of glioma and promote apoptosis and autophagy of glioma cells. Therefore, the doramectin can beused for preparing the medicine for treatment of the glioma, and has a good effect on treatment and prognosis of the glioma.

Description

technical field [0001] The invention relates to the technical field of new uses of medicines, in particular to the application of doramectin in the treatment of glioma. Background technique [0002] Glioma is an aggressive primary central nervous system tumor that causes a large number of glioma patients to die every year. Due to its strong invasiveness and drug resistance, traditional treatment methods cannot completely remove glioma, and the prognosis is poor. Therefore, it is of great significance to develop new treatment methods and chemotherapy drugs for glioma patients. [0003] Doramectin (DRM) is a third-generation derivative drug of abamectin, which belongs to macrolide antiparasitic drugs, and its chemical name is 25-cyclohexyl-5-O-desmethyl- 25-Desabamectin B1, the molecular formula is C 50 h 74 O1 4 , can extensively inhibit parasite activity in animals and in vitro, and is widely used in livestock industry. [0004] So far, the effect of doramectin in the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P35/00
CPCA61K31/7048A61P35/00
Inventor 高爱丽梁洪生杜松林陈晨曲发玲张相彤
Owner NORTHEAST AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products